Surface Therapeutics (acquired by Serentis)
Surface Therapeutics is a drug discovery and development company developing innovative new drugs to treat inflammatory epithelial diseases of the skin and lungs. Surface Therapeutics was acquired by Serentis Inc in September 2007.
Incorporated in November 2004
Origin: Oxford University, Wellcome Trust Centre for Human Genetics